HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Growing Clamor For Oral Contraceptive OTC Switch In UK

Executive Summary

UK parliamentarians have added their voice to the growing calls for the MHRA to switch the daily oral contraceptive pill to OTC status. The COVID-19 pandemic has further highlighted the difficulties women face in accessing contraception, according to the politicians. 

You may also be interested in...



UK Women’s Health Professionals Join Growing Movement For OTC Oral Contraceptives

The UK's Royal College of Obstetricians and Gynaecologists joins a steadily loudening chorus of organizations calling for the prescription-to-OTC switch of oral contraceptives. 

Global Industry Welcomes World Health Organization’s Call For Widespread Oral Contraceptive Rx-To-OTC Switch

The Global Self-Care Industry Federation (previously the WSMI) welcomes a call from the World Health Organization to make oral contraceptive pills available OTC.

Oral Contraceptive OTC Proposal Moves Closer With Start Of Actual Use Study

HRA Pharma started recruiting in April for an actual use trial, using oral contraceptives with norgestrel 0.075 mg, and expects to complete its study in April 2019, according to clinicaltrials.gov's database. Advocacy group Ibis Reproductive Health, which is working with HRA on an NDA for an OTC oral contraceptive, called the start of the study a "pivotal moment" in moving birth control drugs out of Rx-only.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel